UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DA	ATE TE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/643,546	08/19/2003		Jitesh P. Jani	PC23311A	4287	
28940 PFIZER INC	7590	08/09/2007		EXAMINER		
10555 SCIEN	CE CENTER D	RAE, CHARLESWORTH E				
SAN DIEGO,	CA 92121			ART UNIT PAPER NUMBER 1614		
				MAIL DATE	DELIVERY MODE	
				08/09/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

· · · · · · · · · · · · · · · · · · ·		Application	No.	Applicant(s)	· · · · · · · · · · · · · · · · · · ·			
Office Action Summary		10/643,546		JANI ET AL.				
		Examiner		Art Unit				
		Charleswort F	₹ae	1614				
The MAILING DAT	E of this communication app	pears on the co	ver sheet with the c	orrespondence ad	dress			
A SHORTENED STATU WHICHEVER IS LONGE - Extensions of time may be avail after SIX (6) MONTHS from the - If NO period for reply is specifie - Failure to reply within the set or	TORY PERIOD FOR REPLY ER, FROM THE MAILING DA able under the provisions of 37 CFR 1.13 mailing date of this communication. d above, the maximum statutory period v extended period for reply will, by statute later than three months after the mailing See 37 CFR 1.704(b).	ATE OF THIS 136(a). In no event, will apply and will ex e, cause the application	COMMUNICATION however, may a reply be tim pire SIX (6) MONTHS from ion to become ABANDONE	N. nely filed the mailing date of this co	•			
Status								
1) Responsive to con	nmunication(s) filed on <u>22 Se</u>	September 200	<u>4</u> .					
2a) This action is FINA	This action is FINAL . 2b) This action is non-final.							
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordar	nce with the practice under E	Ex parte Quay	e, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims								
4a) Of the above c 5) Claim(s) is/ 6) Claim(s) is/ 7) Claim(s) is/	are rejected.	wn from consi						
Application Papers								
10) The drawing(s) filed Applicant may not re	s objected to by the Examine d on is/are: a) according a distance and a	cepted or b) drawing(s) be h	eld in abeyance. See	e 37 CFR 1.85(a).	FR 1.121(d).			
11) The oath or declara	ation is objected to by the Ex	xaminer. Note	the attached Office	Action or form PT	O-152.			
Priority under 35 U.S.C. §	119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
Attachment(s) 1) Notice of References Cited (2) Notice of Draftsperson's Pate	PTO-892) ent Drawing Review (PTO-948)	4)	☐ Interview Summary Paper No(s)/Mail Da	ate				
3) Information Disclosure State Paper No(s)/Mail Date	ment(s) (PTO/SB/08)	,	Notice of Informal P Other:	atent Application				

DETAILED ACTION

Status of Claims

Claims 1-92 are currently pending in this application and are the subject of the Office action.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-46, and 67, drawn to a method of treating a hyperproliferative disorder in a mammal comprising simultaneously or sequentially administering:
 - (i) a therapeutically effective amount of certain antineopalstic agents, and (ii) a therapeutically effective amount of a compound of formula I, classified as class 514, subclasses 372 and 256. If this Group is elected, then the below Summarized Species Elections is also required.
- II. Claims 47-63, drawn to a pharmaceutical composition comprising above identified ingredient (i) and (ii), classified in class 514, subclass 372. If this Group is elected, then the below Summarized Species Election is also required.
- III. Claims 64-66, drawn to a kit, classified in class 514, subclass 372. If this Group is elected, then the below Summarized Species Election is also required.
- IV. Claims 68-92, drawn to a method of treating a hyperproliferative disorder in a mammal comprising simultaneously or sequentially administering:

Art Unit: 1614

.2

(i) a therapeutically effective amount of certain antineopalstic agents, and

(ii) a therapeutically effective amount of a compound of formula I, and

(iii) a therapeutically effective amount of an anti-hypertensive agent,

classified in class 514, subclasses 372, 256, 381. If this Group is elected,

then the below Summarized Species Election is also required.

Applicant is required to elect a <u>single</u> invention e.g. invention I, for examination

purposes.

Restriction for examination purposes as indicated is proper because all these inventions listed in

this action are independent or distinct for the reasons given above and there would be a serious search and

examination burden if restriction were not required because one or more of the following reasons apply:

(a) the inventions have acquired a separate status in the art in view of their different classification;

(b) the inventions have acquired a separate status in the art due to their recognized divergent

subject matter;

(c) the inventions require a different field of search (for example, searching different

classes/subclasses or electronic resources, or employing different search queries):

(d) the prior art applicable to one invention would not likely be applicable to another invention;

(e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35

U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an

election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143)

and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the

election must be made with traverse. If the reply does not distinctly and specifically point out supposed

errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal

Art Unit: 1614

must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention

Election of Species

This application contains claims directed to the following patentably distinct species e.g. various compounds of formula I, various composition species, and various hyperproliferative disorders. The species are independent or distinct because claims to the different species recite the mutually exclusive characteristics of such species. In addition, these species are not obvious variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a <u>single</u> disclosed species from the below list for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 47, 64, 67, 68, and 91 are generic.

Specifically, applicant is required to elect the following for examination purposes:

1) a single disclosed specifically defined chemical compound species of formula I e.g. 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido)]-isothiazole-4-carboxylic acid amide (see specification, pages 7-11), and

Application/Control Number: 10/643,546

Art Unit: 1614

2) a single disclosed specifically defined composition species wherein each active

ingredient is specifically provided (see pages 12-13), and

3) a single disclosed hyperproliferative disorder species e.g. breast cancer (see

Page 5

specification, page 2, first paragraph).

There is an examination and search burden for these patentably distinct species due to their mutually

exclusive characteristics. The species require a different field of search (e.g., searching different

classes/subclasses or electronic resources, or employing different search queries); and/or the prior art

applicable to one species would not likely be applicable to another species; and/or the species are likely to

raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an

election of a species to be examined even though the requirement may be traversed (37 CFR 1.143) and

(ii) identification of the claims encompassing the elected species, including any claims subsequently

added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive

unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the

election must be made with traverse. If the reply does not distinctly and specifically point out supposed

errors in the election of species requirement, the election shall be treated as an election without traverse.

Traversal must be presented at the time of election in order to be considered timely. Failure to timely

traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added

after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should

submit evidence or identify such evidence now of record showing the species to be obvious variants or

clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species

Art Unit: 1614

unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable. the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double

Application/Control Number: 10/643,546 Page 7

Art Unit: 1614

patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charlesworth Rae whose telephone number is 571-272-6029. The examiner can normally be reached between 9 a.m. to 5:30 p.m. Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached at 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http:pair-direct.uspto.gov. Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 800-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

6 August 2007 CER

BRIAN-YONG S. KWON PRIMARY EXAMINER